Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Peginterferon and Ribavirin for HCV Genotype 2 or 3
NCT00056862Phase 4Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Mar 2003
- Primary completion
- Jan 2010
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Virological Response (Intention to Treat) and Virological Response Category (Per Protocol). Started Mar 2003; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00056862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056862.